COMPASS PATHWAYS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.24 USD | -1.27% |
|
-6.31% | -28.69% |
| 06-05 | Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating | MT |
| 06-04 | FDA panel to review psychedelic drug MDMA for first time | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| COMPASS PATHWAYS PLC | Other Biotechnology & Medical Research | -1.27% | -6.31% | -28.69% | -25.18% | - | 427M |  | |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- CMPS Stock
- Charts COMPASS Pathways plc
- Comparison Chart
